As expected, menin, DOT1L and ENL were all bound to oncoprotein-target sites in the B-ALL sample (Fig. 7a, Supplementary Fig. 6a, b), and both menin and DOT1L were reduced to undetectable levels in the menin-inhibitor-treated AML (Fig. 7a, d, Supplementary Fig. 6a–c). The gene discussed is MEN1; the disease is acute lymphoblastic leukemia.